NCT06180174View on ClinicalTrials.gov

Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/Refractory B Cell Lymphoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 31, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
B Cell LymphomaNon Hodgkin Lymphoma
Interventions
BIOLOGICAL

MC-1-50

A single infusion of CD19 CAR-T cells will be administered intravenously after lymphodepletion

Trial Locations (1)

Unknown

RECRUITING

Beijing Cancer Hospital, Beijing

All Listed Sponsors
collaborator

Peking University Cancer Hospital & Institute

OTHER

lead

Chongqing Precision Biotech Co., Ltd

INDUSTRY